about
Dysregulated metabolism contributes to oncogenesisDesigning a broad-spectrum integrative approach for cancer prevention and treatment.A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells.Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylationCombining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancerPhosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionA colorectal cancer classification system that associates cellular phenotype and responses to therapyFoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cellsA genomic screen identifies TYRO3 as a MITF regulator in melanoma.Targeting metabolic scavenging in pancreatic cancer.Chemical control of stem cell fate and developmental potential.Emerging roles for SIRT5 in metabolism and cancer.Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation.Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.Metabolic Interactions in the Tumor Microenvironment.Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer.Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase.SIRT6 puts cancer metabolism in the driver's seat.Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance.Emerging concepts: linking hypoxic signaling and cancer metabolism.Emerging concepts: linking hypoxic signaling and cancer metabolism.Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis.Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.When Cancer Cells Are Given Lemo[NH3]s, They Make Lemo[NH3]ade.MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers.MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.TUMOR CROSSTALK NETWORKS PROMOTE GROWTH AND SUPPORT IMMUNE EVASION IN PANCREATIC CANCER.
P50
Q26784630-D844CD30-FAEF-4517-9E5D-7F9618D7CBE6Q30736359-D0B18B03-6A8C-4291-91C0-C99BD897EC87Q33966547-573FBBE4-A1FE-4161-847D-85DDB6BE7972Q34360724-A73DD539-613A-4ED7-A041-94F5667613DFQ35223050-FAF45872-F520-4979-AF8F-760AF1D8FC55Q35910406-6662A4F0-B3B7-4D41-9317-FB2EC2BB7CAEQ36131625-B22082B9-804A-4D10-B2F6-C267DE6E5E43Q36844694-40AD45AB-D85A-43B9-9A14-FF8C097D6145Q36850905-4D280A10-63F3-46F6-814F-E8389BE7EFC1Q36928998-3D408F86-94A0-4FFF-93AF-11D7D72E0C63Q37069878-E7677D71-F700-4D05-921A-E6ED059E8748Q37142812-38947542-88F9-470B-A18C-0F51F4430619Q37175913-547A6852-408D-456F-A698-F45E859A384CQ37217384-34947E8E-1059-4A53-86BD-84867BA36426Q37386014-85C581FA-D3EB-41BC-8536-DF224F556920Q37595178-B47F7E65-C68D-42F7-8151-75274683230EQ37823876-48605969-439B-4241-B36C-F186112F59F1Q38657724-1746A98D-05E3-498D-85A0-D9E02D8E9E01Q38696828-56AFD335-A5CE-41A1-B7F1-F677A2111F16Q38727372-A22C7F9D-36E8-4803-8522-2C7156889132Q38798291-9F3DD7EC-7736-4D03-B858-C879A313A2B7Q38830422-54703522-15EF-434E-BBF3-C5ECCF9A1D5EQ38936250-A6801D5B-2178-4A12-9343-C2C7C036579FQ39078244-ABA65438-1D46-4854-A54E-59F495EDE37DQ39452100-EC73E0B6-9BB2-47D2-AF8D-42E04D68F68BQ41034804-9325E647-2F57-4B3E-9AA3-A7F9EF5DC761Q41432721-5EE4AA0A-AFBC-4D09-8948-C4E1BCCB1849Q41874382-55C28C26-1B33-45DA-A8F8-F23D4F989802Q42006846-5E2888BB-CEFE-4CD6-A647-8F1FBEFD11D6Q42544787-4F71790B-A7F7-4DA0-B31F-89F51818B58FQ43188094-F4ACD173-498B-426B-9A6B-A10973BEFD42Q46168258-F2642BEA-BEBE-4720-9816-CA8A30049A62Q46272404-473198D6-FC1C-4003-B5B2-A566D03F33BAQ48046289-60609DFF-8FBC-46F2-B8A0-9863F56C5FD7Q49788157-519B08E0-8013-4C67-80EF-B0487C954414Q50048880-983E5963-9B1F-4328-8432-8DD832F451FCQ50131572-CB062849-D146-4FE9-A7A8-9CA757B5A7A4Q50425330-2B3742B2-3ABD-4962-9666-76CB09549C9AQ50897000-3EBF857B-00C4-40B0-88CC-43E277BC970CQ52354472-A91429A2-37C2-437D-A405-3D13D1195536
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Costas A Lyssiotis
@ast
Costas A Lyssiotis
@en
Costas A Lyssiotis
@es
Costas A Lyssiotis
@fr
Costas A Lyssiotis
@nl
Costas A Lyssiotis
@sl
type
label
Costas A Lyssiotis
@ast
Costas A Lyssiotis
@en
Costas A Lyssiotis
@es
Costas A Lyssiotis
@fr
Costas A Lyssiotis
@nl
Costas A Lyssiotis
@sl
prefLabel
Costas A Lyssiotis
@ast
Costas A Lyssiotis
@en
Costas A Lyssiotis
@es
Costas A Lyssiotis
@fr
Costas A Lyssiotis
@nl
Costas A Lyssiotis
@sl
P106
P21
P31
P496
0000-0001-9309-6141